Novel Retinoic Acid Receptor Alpha Agonists for Treatment of Kidney Disease

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Zhong, Yifei ^c   Wu, Yingwei ^d   Liu, Ruijie ^a   Li, Zhengzhe ^a   Chen, Yibang ^a   Evans, Todd ^b   Chuang, Peter ^a   Das, Bhaskar ^b   He, John Cijiang ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Key Laboratory of Arrhythmias of Ministry of Education   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; BD 4; NEPHRIN; RETINOIC ACID; RETINOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR ALPHA AGONIST; SYNAPTOPODIN; UNCLASSIFIED DRUG; WT1 PROTEIN; ACTIN BINDING PROTEIN; BENZOIC ACID DERIVATIVE; BENZOPYRAN DERIVATIVE; BORON DERIVATIVE; MEMBRANE PROTEIN; RETINOIC ACID RECEPTOR; RETINOID; SYNPO PROTEIN, MOUSE; TETRALIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; FLUOROMETRY; HIGH THROUGHPUT SCREENING; HIV ASSOCIATED NEPHROPATHY; HYDROGEN BOND; HYDROLYSIS; MALE; MOUSE; NONHUMAN; PODOCYTE; PROTEINURIA; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; BINDING COMPETITION; BODY WEIGHT; CELL CULTURE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; MUS MUSCULUS;

AIDS-ASSOCIATED NEPHROPATHY; ANIMALS; BENZOATES; BENZOPYRANS; BINDING, COMPETITIVE; BODY WEIGHT; BORON COMPOUNDS; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; KIDNEY; KIDNEY DISEASES; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MOLECULAR STRUCTURE; PODOCYTES; PROTEINURIA; RECEPTORS, RETINOIC ACID; RETINOIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAHYDRONAPHTHALENES; WT1 PROTEINS;

EID: 84856719284     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027945     Document Type: Article

References (44)

1. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, et al.(2011) US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 57: A8, e1-526.
2. Wyatt CM, Klotman PE, (2007) HIV-associated nephropathy in the era of antiretroviral therapy. Am J Med 120: 488-492.
3. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, et al.(2004) Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 18: 541-546.
4. Barisoni L, Kriz W, Mundel P, D'Agati V, (1999) The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 10: 51-61.
5. Barisoni L, Bruggeman LA, Mundel P, D'Agati VD, Klotman PE, (2000) HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. Kidney Int 58: 173-181.
6. Sunamoto M, Husain M, He JC, Schwartz EJ, Klotman PE, (2003) Critical role for Nef in HIV-1-induced podocyte dedifferentiation. Kidney Int 64: 1695-1701.
7. He JC, Husain M, Sunamoto M, D'Agati VD, Klotman ME, et al.(2004) Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Invest 114: 643-651.
8. Zhong J, Zuo Y, Ma J, Fogo AB, Jolicoeur P, et al.(2005) Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int 68: 1048-1060.
9. Evans TR, Kaye SB, (1999) Retinoids: present role and future potential. Br J Cancer 80: 1-8.
10. Merlet-Benichou C, Vilar J, Lelievre-Pegorier M, Gilbert T, (1999) Role of retinoids in renal development: pathophysiological implication. Curr Opin Nephrol Hypertens 8: 39-43.
11. Xu Q, Lucio-Cazana J, Kitamura M, Ruan X, Fine LG, et al.(2004) Retinoids in nephrology: promises and pitfalls. Kidney Int 66: 2119-2131.
12. Lehrke I, Schaier M, Schade K, Morath C, Waldherr R, et al.(2002) Retinoid receptor-specific agonists alleviate experimental glomerulonephritis. Am J Physiol Renal Physiol 282: F741-751.
13. Wagner J, Dechow C, Morath C, Lehrke I, Amann K, et al.(2000) Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J Am Soc Nephrol 11: 1479-1487.
14. Moreno-Manzano V, Mampaso F, Sepulveda-Munoz JC, Alique M, Chen S, et al.(2003) Retinoids as a potential treatment for experimental puromycin-induced nephrosis. Br J Pharmacol 139: 823-831.
15. Suzuki A, Ito T, Imai E, Yamato M, Iwatani H, et al.(2003) Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol 14: 981-991.
16. Schaier M, Lehrke I, Schade K, Morath C, Shimizu F, et al.(2001) Isotretinoin alleviates renal damage in rat chronic glomerulonephritis. Kidney Int 60: 2222-2234.
17. Perez de Lema G, Lucio-Cazana FJ, Molina A, Luckow B, Schmid H, et al.(2004) Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. Kidney Int 66: 1018-1028.
18. Han SY, So GA, Jee YH, Han KH, Kang YS, et al.(2004) Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol 82: 568-576.
19. Vaughan MR, Pippin JW, Griffin SV, Krofft R, Fleet M, et al.(2005) ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo. Kidney Int 68: 133-144.
20. He JC, Lu TC, Fleet M, Sunamoto M, Husain M, et al.(2007) Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol 18: 93-102.
21. Lu TC, He JC, Wang ZH, Feng X, Fukumi-Tominaga T, et al.(2008) HIV-1 Nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein. J Biol Chem 283: 8173-8182.
22. Montesinos P, Bergua JM, Vellenga E, Rayon C, Parody R, et al.(2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113: 775-783.
23. Ratnam KK, Feng X, Chuang PY, Verma V, Lu TC, et al.(2011) Role of the retinoic acid receptor-alpha in HIV-associated nephropathy. Kidney Int 79: 624-634.
24. Waugh KM, Berlin KD, Ford WT, Holt EM, Carrol JP, et al.(1985) Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide and ethyl (E)-p-[2-(4,4-dimethylthiochroman-6-yl)propenyl]benzoate. J Med Chem 28: 116-124.
25. Benbrook DM, Madler MM, Spruce LW, Birckbichler PJ, Nelson EC, et al.(1997) Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. J Med Chem 40: 3567-3583.
26. Benbrook DM, Subramanian S, Gale JB, Liu S, Brown CW, et al.(1998) Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships. J Med Chem 41: 3753-3757.
27. Vuligonda V, Chandraratna RA, (1999) A short and efficient synthesis of 4-[2,2-dimethyl-4(tol-4-yl)benzochrom-3-en-7-yl]benzoic acid- a potent retinoic acid receptor antagonist. Bioorg Med Chem Lett 9: 2289-2290.
28. Yang W, Gao X, Wang B, (2003) Boronic acid compounds as potential pharmaceutical agents. Med Res Rev 23: 346-368.
29. Koehler KA, Lienhard GE, (1971) 2-phenylethaneboronic acid, a possible transition-state analog for chymotrypsin. Biochemistry 10: 2477-2483.
30. Fevig TL, Bowen SM, Janowick DA, Jones BK, Munson HR, et al.(1996) Design, synthesis, and in vitro evaluation of cyclic nitrones as free radical traps for the treatment of stroke. J Med Chem 39: 4988-4996.
31. Asano T, Nakamura H, Uehara Y, Yamamoto Y, (2004) Design, synthesis, and biological evaluation of aminoboronic acids as growth-factor receptor inhibitors of EGFR and VEGFR-1 tyrosine kinases. Chembiochem 5: 483-490.
32. Das BC, McCartin K, Liu TC, Peterson RT, Evans T, (2010) A forward chemical screen in zebrafish identifies a retinoic acid derivative with receptor specificity. PLoS One 5: e10004.
33. Das BC, Madhukumar AV, Anguiano J, Mani S, (2009) Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics. Bioorg Med Chem Lett 19: 4204-4206.
34. Torregroza I, Evans T, Das BC, (2009) A forward chemical screen using zebrafish embryos with novel 2-substituted 2H-chromene derivatives. Chem Biol Drug Des 73: 339-345.
35. Das BC, Smith ME, Kalpana GV, (2008) Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors. Bioorg Med Chem Lett 18: 4177-4180.
36. Das BC, Smith ME, Kalpana GV, (2008) Design and synthesis of 4-HPR derivatives for rhabdoid tumors. Bioorg Med Chem Lett 18: 3805-3808.
37. Jubinsky PT, Short MK, Ghanem M, Das BC, (2011) Design, synthesis, and biological activity of novel Magmas inhibitors. Bioorg Med Chem Lett 21: 3479-3482.
38. Dawson MI, Chao WR, Pine P, Jong L, Hobbs PD, et al.(1995) Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res 55: 4446-4451.
39. Shankland SJ, Pippin JW, Reiser J, Mundel P, (2007) Podocytes in culture: past, present, and future. Kidney Int 72: 26-36.
40. de The H, Vivanco-Ruiz MM, Tiollais P, Stunnenberg H, Dejean A, (1990) Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. Nature 343: 177-180.
41. Delescluse C, Cavey MT, Martin B, Bernard BA, Reichert U, et al.(1991) Selective high affinity retinoic acid receptor alpha or beta-gamma ligands. Mol Pharmacol 40: 556-562.
42. Look J, Landwehr J, Bauer F, Hoffmann AS, Bluethmann H, et al.(1995) Marked resistance of RAR gamma-deficient mice to the toxic effects of retinoic acid. Am J Physiol 269: E91-98.
43. D'Agati V, (2003) Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 23: 117-134.
44. Takemoto M, Asker N, Gerhardt H, Lundkvist A, Johansson BR, et al.(2002) A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 161: 799-805.